INmune Bio (INMB) Announces Approximately $19 Million Registered Direct Offering

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.

The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.

You May Also Be Interested In

• Adaptive Biotechnologies issues $345M in convertible notes due 2031
• NVE Corp CEO to retire, successor named for August transition
• Rocket Lab launches U.S. Space Force mission in record 16 hours